122018-58-0

Basic information

• Product Name: PLP (139-151)
• Synonyms: [Ser140] Myelin Proteolipid Protein (139-151);(Ser140)-Myelin Proteolipid Protein (139-151) (depalMitoylated) (huMan, bovine, dog, Mouse, rat) (Ser140)-Lipophilin (139-151) (depalMitoylated) (huMan, bovine, dog, Mouse, rat), (Ser140)-PLP (139-151) (depalMitoylated) (huMan, bovine, dog, Mouse, rat);(Ser140)-Lipophilin (139-151) (depalMitoylated) (huMan, bovine, dog, Mouse, rat), (Ser140)-PLP (139-151) (depalMitoylated) (huMan, bovine, dog, Mouse, rat);myelin PLP139-151|PLP (139-151);PROTEOLIPID PROTEIN;PLP (HUMAN, BOVINE, DOG, MOUSE, RAT);PLP (139-151);MYELIN PROTEOLIPID PROTEIN FRAGMENT (139-151)
• CAS NO: 122018-58-0
• Molecular Formula: C72H104N20O17
• Molecular Weight: 1521.72
• Product Categories: Peptide
• Mol File: 122018-58-0.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 1915.3±65.0 °C(Predicted)
• Appearance: /
• Density: 1.337±0.06 g/cm3(Predicted)
• Storage Temp.: -15°C
• PKA: 3.49±0.10(Predicted)
• CAS DataBase Reference: PLP (139-151)(CAS DataBase Reference)
• NIST Chemistry Reference: PLP (139-151)(122018-58-0)
• EPA Substance Registry System: PLP (139-151)(122018-58-0)

Safety Data

• Hazardous Substances Data: 122018-58-0(Hazardous Substances Data)

Usage

General Description

PLP (139-151) is a peptide composed of 13 amino acids, with the sequence YRGRFLYDTKGNYT, that has been shown to have an immunomodulatory effect. This peptide has been studied for its potential therapeutic applications in conditions such as multiple sclerosis, where it has been found to inhibit the proliferation of autoreactive T cells and reduce inflammation. Additionally, PLP (139-151) has been studied for its potential role in promoting tolerance and preventing autoimmune responses. Its mechanism of action is thought to involve the regulation of immune cell activity and cytokine production. Overall, PLP (139-151) shows promise as a potential therapeutic agent for immune-related disorders.

Relevant articles and documents

IMMUNOMODULATING COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF HUMAN AUTOIMMUNE DISEASES

A composition and method for treating an autoimmune condition are disclosed. The composition includes of an immunomodulating compound composed of a central amino acid core having a plurality of chemical attachment groups, and a plurality of antigenic peptides which are (i) associated with an auto-immune disorder and (?) attached to the core groups with the same N-terminus to C-terminus orientation. The compound is carried in a pharmaceutically acceptable carrier. An exemplary compound has an octomeric polylysine core and eight antigenic peptides, such as the peptides identified by SEQ ID NOS: 1-11, attached thereto. The compound is effective in treating an autoimmune disorder, by administering to a subject in need of the treatment, a pharmaceutically effective amount of the compound.